锕-225 前列腺特异性膜抗原放射性药物治疗：α 疗法会优于 β 疗法吗？
Actinium-225 Prostate-specific Membrane Antigen Theranostics: Will α Beat β?
机构信息
Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; The Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
出版信息
Eur Urol. 2021 Mar;79(3):351-352. doi: 10.1016/j.eururo.2020.12.011. Epub 2021 Jan 9.
PMID:33436167
Abstract
Optimisation of prostate-specific membrane antigen (PSMA) based radioligand therapy (RLT) requires a focus on prospective trials.
摘要
优化基于前列腺特异性膜抗原（PSMA）的放射性配体治疗（RLT）需要侧重于前瞻性试验。
Zotero 插件